UB Therapeutics

Therapy for the Treatment of Multiple Myeloma

Health Tech & Life Sciences
Active
Pre-Seed Nazareth, Israel Founded 2023
Last updated 2026-06-18
Total raised
$415K
Last: 2023-02
Stage
Pre-Seed
Founded
2023
Headcount
2
HQ
Nazareth, Israel
Sector
Health Tech & Life Sciences

About

UB Therapeutics is a biotechnology company developing a novel therapy for the treatment of multiple myeloma. The company’s compound is a cyclic peptide with potential anticancer therapeutic activity. The cyclic peptides block the action of deubiquitinases and the proteasome, induce apoptosis in vitro, and attenuate tumor growth in vivo.

These cyclic peptides show in vitro and in vivo activity comparable to a small molecule proteasome inhibitor and similarly induce apoptosis in cancer cells. Whereas the immediate target of small molecules proteasome inhibitors such as bortezomib is the chymotrypsin-like β5 catalytic subunit of the proteasome, the cyclic peptides impair the recognition and subsequent proteasomal degradation of ubiquitinylated proteins.

Funding history · 1 round · $415K total

Q&A

What is UB Therapeutics' primary focus?
UB Therapeutics is a biotechnology company developing a novel therapy for the treatment of multiple myeloma.
What type of compound is UB Therapeutics developing?
The company's compound is a cyclic peptide with potential anticancer therapeutic activity, designed to block deubiquitinases and the proteasome.
When was UB Therapeutics founded?
UB Therapeutics was founded in January 2023.
How many employees does UB Therapeutics currently have?
UB Therapeutics has 1-10 employees.
What is the total amount of funding UB Therapeutics has raised to date?
UB Therapeutics has raised a total of $415,415 USD.
When was UB Therapeutics' last funding round and who were the investors?
In February 2023, UB Therapeutics secured funding from NGT HealthCare II and Israel Innovation Authority.
What is UB Therapeutics' current funding stage?
UB Therapeutics is currently in the Pre-Seed funding stage.
Who is the founder of UB Therapeutics?
Ashraf Brik is the founder of UB Therapeutics.

Team · 1

Founder · Founder
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesBiotechnology
Business model
B2B2C

Tags

cancer-therapyhealthcarebiotechnologypharmaceuticalscancer
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)